Several highly selective inhibitors of CDK4 and CDK6 are currently being tested in phase II/III clinical trials against a variety of pRb-proficient chemotherapy-resistant cancers (http://ClinicalTrials.gov) [30, 31]. The gene discussed is CDK4; the disease is cancer.